Abstract
Inflammatory bowel diseases (IBDs) are chronic and involve the gastrointestinal tract; the two primary IBDs are ulcerative colitis and Crohn’s disease. Existing treatments for IBD include control of active inflammation and regulation of immune disorders, and commonly used drugs include salicylates, corticosteroids, and immunosuppressants. At the same time, an in-depth study of IBD pathogenesis promoted the acceptance of bioimmunotherapy by increasing numbers of people. However, long-term use of these drugs can cause adverse reactions that are difficult for patients to overcome, with limited efficacy for critically ill patients. Recent studies have found that stem cell transplantation is a new and effective therapy and IBD treatment, particularly for refractory cases. Stem cells, especially induced pluripotent stem cells (iPSCs), can differentiate into functional intestinal epithelia and their use avoids ethical issues arising from embryonic stem cells, providing a new kind of seed cell for alternative treatments for IBD. This paper reviews iPSCs as a potential new treatment for IBDs in order to provide an experimental and clinical reference.
Keywords: Induced pluripotent stem cells, inflammatory bowel diseases, intestinal epithelial cell, reprogramming.
Current Stem Cell Research & Therapy
Title:Applications of Induced Pluripotent Stem Cells in the Modeling of Human Inflammatory Bowel Diseases
Volume: 10 Issue: 3
Author(s): Jingquan Liu, Bin Shi, Kai Shi and Hongze Zhang
Affiliation:
Keywords: Induced pluripotent stem cells, inflammatory bowel diseases, intestinal epithelial cell, reprogramming.
Abstract: Inflammatory bowel diseases (IBDs) are chronic and involve the gastrointestinal tract; the two primary IBDs are ulcerative colitis and Crohn’s disease. Existing treatments for IBD include control of active inflammation and regulation of immune disorders, and commonly used drugs include salicylates, corticosteroids, and immunosuppressants. At the same time, an in-depth study of IBD pathogenesis promoted the acceptance of bioimmunotherapy by increasing numbers of people. However, long-term use of these drugs can cause adverse reactions that are difficult for patients to overcome, with limited efficacy for critically ill patients. Recent studies have found that stem cell transplantation is a new and effective therapy and IBD treatment, particularly for refractory cases. Stem cells, especially induced pluripotent stem cells (iPSCs), can differentiate into functional intestinal epithelia and their use avoids ethical issues arising from embryonic stem cells, providing a new kind of seed cell for alternative treatments for IBD. This paper reviews iPSCs as a potential new treatment for IBDs in order to provide an experimental and clinical reference.
Export Options
About this article
Cite this article as:
Liu Jingquan, Shi Bin, Shi Kai and Zhang Hongze, Applications of Induced Pluripotent Stem Cells in the Modeling of Human Inflammatory Bowel Diseases, Current Stem Cell Research & Therapy 2015; 10 (3) . https://dx.doi.org/10.2174/1574888X09666140820162716
DOI https://dx.doi.org/10.2174/1574888X09666140820162716 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine Nanomedical Platform for Drug Delivery in Cancer
Current Organic Chemistry Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Steroidal Cardiac Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors Exhibit Strong Anti-Cancer Potential <i>in vitro</i> and in Prostate and Lung Cancer Xenografts <i>in vivo</i>
Anti-Cancer Agents in Medicinal Chemistry Pleiotropic Role of HSF1 in Neoplastic Transformation
Current Cancer Drug Targets Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Subject Index to Volume 10
Current Medicinal Chemistry The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets Cytotoxic and Allergenic Potential of Bioactive Proteins and Peptides
Current Pharmaceutical Design Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets Analysis of the Concordance in the EGFR Pathway Status Between Primary Tumors and Related Metastases of Colorectal Cancer Patients:Implications for Cancer Therapy
Current Cancer Drug Targets Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic:Angiogenesis Agents(Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Connecting A Tumor to the Environment
Current Pharmaceutical Design Angiogenesis as a therapeutic target in breast cancer
Mini-Reviews in Medicinal Chemistry Metastatic Brain Tumors: To Treat or Not to Treat, and with What?
Current Cancer Therapy Reviews Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Azathioprine, Mucosal Healing in Ulcerative Colitis, and the Chemoprevention of Colitic Cancer: A Clinical-Practice-Based Forecast
Inflammation & Allergy - Drug Targets (Discontinued)